RX PHARMA HOME PAGE
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
| |
|
|
|
 |
 |
 |
|
| |
|
|
|
|
| |
Generic drugs are believed indistinguishable, or bioequivalent to the brand-name originals.
|
| |
They comprise the identical dynamic contents and have the similar excellence, effectiveness and wellbeing. |
| |
Generics may comprise diverse static components that do not have therapeutic result. |
| |
|
|
|
|
| |
Medicinal drug will frequently have more than one name:
|
| |
A generic name, which is the dynamic component of the medicine.
|
| |
A brand name, which is the trade name the producer, gives to the medicine.
|
| |
The generic name is the authorized medical name for the dynamic component of the medicine.
|
| |
The brand name is selected by the producer, normally on the standard that it can be distinguished, marked and called back by health professionals as well as members of the public. An instance would be Viagra this is the long-familiar brand name given by Pfizer to the generic drug Sildenafil.
|
| |
Brand names are capitalized; generic names are not.
|
|
|
|
| |
|
| |
The brand name is the label in which a new pioneer medicinal drug is formulated and commercialized.
|
| |
When a pharmacy formulates a new medication, they get patent for it. Brands are generally given patent protection for about 20 years. |
| |
When the patent of a brand-name drug dies, other companies can bring in its generic adaptation. |
| |
|
| |
Generics are as safe and sound as efficient as the brand-name drugs.
|
| |
They express precisely the similar pharmacologic and clinical results. |
| |
They have the similar risks as well as advantages as the brand-name products. |
| |
|
|
|
The generic products are required to be bioequivalent to the originator medication.
|
|
|
As generic medicinal drugs comprise the similar active agent content, there is no necessity to repeat the pharmacological and clinical tests made with the original.
|
|
|
As an alternative, they are replaced by clinical studies.
|
|
|
Both drugs are measured bioequivalent when they demonstrate similar rate and amount of amalgamation in the human organism.
|
| |
|
|
|
Equally brands and generics are of the similar quality, as their readiness’s have to get together the similar authoritarian productions measures of Good Manufacturing Practice (GMP)
|
| |
|
|
|
Generic drugs are substantially a smaller amount than the brand-name products.
|
|
|
As the generic producer do not have the costs necessary for development of an original product.
|
|
|
The price of the generic medicinal drugs are 30% to 80% lesser than the price of the same brand name.
|
| |
|
|
|
Generic medicinal drugs furnish a major benefit to the society.
|
|
|
The healthcare systems put aside much money by the use of cost-efficient generics.
|
|
|
In relation to 50% of all prescriptions in the United States, as well as more than 40% of all prescriptions in Canada are overflowing with generic medicinal drug.
|
|
|
Acted out in 1984, the U.S. Drug Price Competition and Patent Term Restoration Act unofficially acknowledged as the “Hatch-Waxman Act”, standardized U.S. procedures for identification of generic drugs.
|
|
|
A claimant files an Abbreviated New Drug Application or “ANDA” with the Food and Drug Administration (FDA) and seeks to manifest therapeutic comparison to a defined, antecedently sanctioned “reference listed drug”.
|
|
|
When an ANDA is approved, the FDA contributes the medicine to its Approved Drug Products list, also acknowledged as the “Orange Book”, and annotates the listing to demonstrate likeness amid the suggestion listed medicine and the permitted generic.
|
|
|
The FDA also distinguishes medicine using the same components with dissimilar bioavailability and separates them into therapeutic comparison groups.
|
|
|
On October 4, 2007, FDA commenced the Generic Initiative for Value and Efficiency, or else GIVE.
|
|
|
The proposal will use accessible resources to facilitate FDA update and make more efficient the generic drug authorization process.
|
|
|
GIVE aims to increment the number as well as diversity of generic drug products accessible. Featuring additional generic-drug options entails more cost-savings to customers, as generic drugs price about 30% to 80% less than trademark name drugs.
|
|
|
In the United States, generic drug substances are listed all the way through appraisal and commendation of the United States Adopted Names (USAN) Council.
|
|
|
|
|
|
|
|
|
|
| |
| |
|
|
|
|